Results 91 to 100 of about 21,131 (181)

Targeting SLC5A2 suppresses colorectal tumour development by enhancing NK cell activity through extracellular vesicle-dependent MICA/B signalling. [PDF]

Clin Transl Med
Xiao J, Wu J, Deng F, Liu C, Chen Y, Shen K, Wang C, Lin W, Liu W, Ning Z, Zhou R, Zhao L.   +11 more
europepmc   +1 more source

Molecular Competition for NKG2D [PDF]

Immunity, 2001
O'Callaghan, Christopher A, Cerwenka, Adelheid, Willcox, Benjamin E, Lanier, Lewis L, Bjorkman, Pamela J   +4 more
openaire   +1 more source

NKG2D CAR-T cells for solid tumor immunotherapy: advances, challenges, and future directions. [PDF]

Front Immunol
Liu C, Wang Z, Zhang W, Cheng G, Cheng S, Qin L, Ye H, Ren W.   +7 more
europepmc   +1 more source

Targeting endosomal trafficking-mediated antigen escape to resensitize myeloma to CAR-T therapy. [PDF]

J Immunother Cancer
Wang Z, Wang G, Liu Y, Zhao Y, Guo S, Yang Y, Zhang Q, Hu C, Chang S, Wu X, An D, Hu H, Cai H, Zhang L, Shi J.   +14 more
europepmc   +1 more source

Harnessing the NKG2D immune surveillance pathway using engineered T-cells for the treatment of human disease. [PDF]

Hum Vaccin Immunother
Glover M, Maher J, Davies DM.
europepmc   +1 more source

Major histocompatibility complex class I chain-related A and B molecules and their potential role in virus-associated cancers. [PDF]

World J Virol
Bouayad A.
europepmc   +1 more source

Unaltered NKG2D-CAR T cell function under hypoxia in osteosarcoma in vitro. [PDF]

Cancer Immunol Immunother
Hidalgo L, Garcia-Rodriguez P, Cubillo I, Zubizarreta M, Perez-Martinez A, García-Castro J.   +5 more
europepmc   +1 more source

NKGD2 Ligands (NKG2DLs) in Breast Cancer: In Silico Analysis and Narrative Review. [PDF]

Int J Mol Sci
Peña-López J, Gámez-Pozo A, Trilla-Fuertes L, Becerril-Gómez F, Mendiola M, Heredia V, Yébenes L, Castelo B, Martínez-Marín V, Espinosa E, Zamora P, Alba-Bernal A, Aguirre-Portolés C, Pérez-Martínez A.   +13 more
europepmc   +1 more source

Targeting NKG2DLs with an ADCC enhanced fusion protein for induction of NK cell reactivity against ovarian cancer. [PDF]

J Ovarian Res
Hagelstein I, Wang K, Hölz A, Blessing J, Lutz MS.   +4 more
europepmc   +1 more source

Natural killer cell dysfunction in glioma: from immune evasion to immunotherapy. [PDF]

Front Immunol
Zhang R, Ma P, Tang K, Cao Y, Yang Y, Hao S, Li T, Peng X.   +7 more
europepmc   +1 more source